VCM
NKTR icon

Voleon Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Voleon Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.85M Sell
40,838
-24,225
-37% -$1.77M 0.05% 296
2026
Q1 		$4.68M Sell
65,063
-3,272
-5% -$186K 0.1% 212
2025
Q4 		$2.89M Buy
+68,335
New +$3.82M 0.06% 288

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Voleon Capital Management's NKTR Position: Q2 2026 in Review

Voleon Capital Management reduced its Nektar Therapeutics (NKTR) stake by 37% in Q2 2026, selling an estimated $1.77M and leaving 40,838 shares worth $2.85M. The position accounts for 0.05% of the portfolio, ranked #296.

Voleon Capital Management first reported a position in NKTR in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.68M in Q1 2026. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Voleon Capital Management held 40,838 shares of Nektar Therapeutics worth $2.85M as of Q2 2026.
  • Voleon Capital Management sold 24,225 Nektar Therapeutics shares in Q2 2026, an estimated $1.77M.
  • Nektar Therapeutics made up 0.05% of Voleon Capital Management's portfolio in Q2 2026, its #296 holding.
  • Voleon Capital Management first reported a position in Nektar Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Voleon Capital Management's Nektar Therapeutics position peaked at $4.68M in Q1 2026.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Voleon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.